Documents : Union européenne

Union supranationale de 27 États membres. Les actes officiels (règlements, directives, décisions) sont publiés par l'Office des publications de l'UE (Cellar/EUR-Lex). La jurisprudence de la Cour de justice de l'UE (CJUE) relève également d'un organe de l'UE.

Site officiel ↗

Types de documents
regulation (161354) cjeu_case (104315) decision (43245) directive (8067)
316 981 documents
46661

Judgment of the Court (Fourth Chamber) of 25 March 2021.#Generics (UK) Ltd v European Commission.#Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressants (citalopram) – Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.#Case C-588/16 P.

cjeu_case ·
46662

Judgment of the Court (Fourth Chamber) of 25 March 2021.#Generics (UK) Ltd v European Commission.#Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressants (citalopram) – Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.#Case C-588/16 P.

cjeu_case ·
46663

Judgment of the Court (Fourth Chamber) of 25 March 2021.#Sun Pharmaceutical Industries Ltd and Ranbaxy (UK) Ltd v European Commission.#Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressant medicines (citalopram) – Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.#Case C-586/16 P.

cjeu_case ·
46664

Judgment of the Court (Fourth Chamber) of 25 March 2021.#Sun Pharmaceutical Industries Ltd and Ranbaxy (UK) Ltd v European Commission.#Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressant medicines (citalopram) – Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.#Case C-586/16 P.

cjeu_case ·
46665

Case C-614/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Merck KGaA v European Commission, Generics (UK) Ltd (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressant medicines (citalopram) — Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine)

cjeu_case ·
46666

Case C-611/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Xellia Pharmaceuticals ApS, Alpharma LLC, formerly Zoetis Products LLC v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressants (citalopram) — Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine — Rights of the defence — Reasonable time — Loss of documents due to the passage of time — General duty of care — Regulation (EC) No 1/2003 — Second subparagraph of Article 23(2) — Maximum amount of the fine — Taking into account the business year preceding that in which the European Commission’s decision was adopted — Last full year of normal economic activity)

cjeu_case ·
46667

Case C-601/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Arrow Group ApS, Arrow Generics Ltd v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressant medicines (citalopram) — Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine)

cjeu_case ·
46668

Case C-591/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — H. Lundbeck A/S, Lundbeck Ltd v European Commission, European Federation of Pharmaceutical Industries and Associations (EFPIA) (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressants (citalopram) — Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine — Sales directly or indirectly related to the infringement)

cjeu_case ·
46669

Case C-588/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Generics (UK) Ltd v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressants (citalopram) — Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine)

cjeu_case ·
46670

Case C-586/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Sun Pharmaceutical Industries Ltd, formerly Ranbaxy Laboratories Ltd, Ranbaxy (UK) Ltd v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressant medicines (citalopram) — Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine)

cjeu_case ·
46675

Commission Delegated Regulation (EU) 2021/923 of 25 March 2021 supplementing Directive 2013/36/EU of the European Parliament and of the Council with regard to regulatory technical standards setting out the criteria to define managerial responsibility, control functions, material business units and a significant impact on a material business unit’s risk profile, and setting out criteria for identifying staff members or categories of staff whose professional activities have an impact on the institution’s risk profile that is comparably as material as that of staff members or categories of staff referred to in Article 92(3) of that Directive (Text with EEA relevance)

regulation ·